文献速递冠心病血脂与心血管预防

撤稿:阿托伐他汀负荷剂量对急性冠脉综合征PCI患者主要不良心血管事件短期和长期影响的荟萃分析

RETRACTED: Short-term and long-term effects of a loading dose of atorvastatin before percutaneous coronary intervention on major adverse cardiovascular events in patients with acute coronary syndrome: a meta-analysis of 13 randomized controlled trials.
PubMed 文献 · Eur Heart J · 2019-01-01

AIMS: Whether a loading dose of atorvastatin (80 mg) can reduce major adverse cardiovascular events (MACE) in patients with acute coronary syndrome (ACS) remains controversial. Therefore, we performed this meta-analysis.…

要点

  • 该荟萃分析结果提示阿托伐他汀80mg负荷剂量可降低ACS行PCI患者MACE,但原文已撤稿。
  • 合并结果显示MI、血运重建和卒中风险降低,死亡或再住院无差异。
  • 亚组分析显示30天内及30天后MACE均降低,但证据因撤稿需谨慎解读。

核心结论

  • 该荟萃分析支持阿托伐他汀负荷剂量可显著降低ACS患者心血管事件,但该文已被撤稿。

主要发现

  • 与对照相比,阿托伐他汀显著降低MACE(RR 0.66,95%CI 0.54-0.80)、心肌梗死(RR 0.61,95%CI 0.46-0.80)、血运重建(RR 0.76,95%CI 0.69-0.83)和卒中(RR 0.69,95%CI 0.49-0.96)。
  • 两组死亡或再住院无差异。
  • 亚组分析显示30天内MACE(RR 0.57,95%CI 0.39-0.85)和MI(RR 0.61,95%CI 0.42-0.89)显著降低。
  • 30天以上MACE(RR 0.70,95%CI 0.55-0.89)、MI(RR 0.58,95%CI 0.36-0.95)和血运重建(RR 0.76,95%CI 0.69-0.84)显著降低。
  • 30天内或30天以上死亡或卒中无显著差异。

局限性

  • 该文已被撤稿,原文摘要未报告具体撤稿原因及局限性细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Whether a loading dose of atorvastatin (80 mg) can reduce major adverse cardiovascular events (MACE) in patients with acute coronary syndrome (ACS) remains controversial. Therefore, we performed this meta-analysis. METHODS AND RESULTS: Randomized controlled trials (RCT) comparing a loading dose of atorvastatin to a control in patients with ACS who underwent PCI were identified through searches of medical literature databases. Risk ratios (RRs) and 95% confidence intervals (CIs) were calculated to compare the primary endpoint. Finally, 13 trials enrolling 22 095 patients were included; of the 22 095 patients, 11 214 (50.7%) received loading doses of 80 mg of atorvastatin. Compared with the control, atorvastatin significantly reduced MACE (RR: 0.66, 95% CI 0.54-0.80), myocardial infarction (MI; RR: 0.61, 95% CI 0.46-0.80), revascularization (RR: 0.76, 95% CI 0.69-0.83), and stroke (RR: 0.69, 95% CI 0.49-0.96). There was no difference in death or rehospitalization between the two groups. In the subgroup analysis, atorvastatin still significantly reduced MACE (RR: 0.57, 95% CI 0.39-0.85) and MI (RR: 0.61, 95% CI 0.42-0.89) within 30 days. Furthermore, atorvastatin still remarkably reduced MACE (RR: 0.70, 95% CI 0.55-0.89), MI (RR: 0.58, 95% CI 0.36-0.95), and revascularization (RR: 0.76, 95% CI 0.69-0.84) after more than 30 days. No significant differences were observed in death or stroke within 30 days or after more than 30 days. CONCLUSION: Our meta-analysis supports the concept that a loading dose of atorvastatin markedly reduces cardiovascular events in patients with ACS.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Ye Z, Lu H, Su Q, et al. RETRACTED: Short-term and long-term effects of a loading dose of atorvastatin before percutaneous coronary intervention on major adverse cardiovascular events in patients with acute coronary syndrome: a meta-analysis of 13 randomized controlled trials. Eur Heart J. 2019. PMID: 30608526. doi:10.1093/eurheartj/ehy833

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。